The James J. Peters Veterans Administration Medical Center in Bronx, NY. has begun a new, national Alzheimer’s disease (AD) clinical research study evaluating the potential benefits of an investigational medicine for people diagnosed with mild-to-moderate AD.
The Phase 2 study, called T2 Protect AD, is evaluating the investigational drug troriluzole, which may have the potential to protect against, slow down, and eventually improve memory and thinking problems that increase as Alzheimer’s disease progresses. Troriluzole is a drug that modulates glutamate, protecting against neuron loss. Glutamate problems in the brain can lead to brain cell dysfunction and disease, including Alzheimer’s disease.
Troriluzole is a prodrug of riluzole, a drug first approved by the Federal Drug Administration in 1995 to slightly slow disease progression in patients with Amyotrophic Lateral Sclerosis (ALS). A prodrug is an inactive medication that changes into a drug after ingestion.
Clinicians at the James J. Peters VAMC are now seeking eligible candidates for the T2 Protect AD study. To participate in T2 Protect AD, candidates must be between age 50 and 85 and diagnosed with mild-to-moderate Alzheimer’s disease, and already being treated with donepezil (Aricept), rivastigmine (Exelon®) or galantamine (Razadyne®) for at least three months, with or without memantine (Namenda®). Participants must have a study partner who has regular contact with the clinical trial candidate and is able to attend study visits.
The study is sponsored by New Haven-based Biohaven Pharmaceutical Holding Company Ltd., and is coordinated by the Alzheimer’s Disease Cooperative Study (ADCS), based at the University of California, San Diego.
For more information on participating at James J. Peters VAMC, please call 718-584-9000.
For more information on other T2 Study sites around the country, please visit T2Protect.org.